Abstract As part of the development of the National Institute for Health and Care Excellence (NICE) Medical Technologies Guidance on Parafricta Bootees and Undergarments to reduce skin breakdown in people with, or at risk of, pressure ulcers, the manufacturer (APA Parafricta Ltd) submitted clinical and economic evidence, which was critically appraised by an External Assessment Centre (EAC) and subsequently used by the Medical Technologies Advisory Committee (MTAC) to develop recommendations for further research. The University of Birmingham and Brunel University, acting as a consortium, were commissioned to act as the EAC, independently appraising the submission. This article is an overview of the original evidence submitted, the EAC's findings and the final NICE guidance. Very little comparative evidence was submitted to demonstrate the effectiveness of Parafricta Bootees or Undergarments. The sponsor submitted a simple cost analysis to estimate the costs of using Parafricta in addition to current practice-in comparison with current practice alone-in hospital and community settings separately. The analysis took a National Health Service (NHS) perspective. The basis of the analysis was a previously published comparative study, which showed no statistical difference in average lengths of stay between patients who wore Parafricta Undergarments and Bootees, and those who did not. The economic model incorporated the costs of Parafricta but assumed shorter lengths of stay with Parafricta. The sponsor concluded that Parafricta was cost saving relative to the comparators. The EAC made amendments to the sponsor's analysis to correct for errors and to reflect alternative assumptions. Parafricta remained cost saving in most analyses, and the savings per prevalent case ranged from £757 in the hospital model to £3455 in the community model. All analyses were severely limited by the available data on effectiveness-in particular, a lack of good-quality comparative studies.
Introduction
The Medical Technologies Evaluation Programme (MTEP) of the National Institute for Health and Care Excellence (NICE) produces evidence-based Medical Technologies Guidance with the overall aim of evaluating and, where appropriate, encouraging adoption of novel and innovative medical devices and diagnostic tools within the National Health Service (NHS) in England. Manufacturers or distributors of potentially eligible technologies notify their products to MTEP. Notified technologies must have a Conformité Européenne (CE) mark or expect one within the next 12 months, and must have the potential either to offer significant clinical benefits to patients and the NHS at the same cost as current practice, or to reduce cost with the same clinical benefit. Technologies that the Medical Technologies Advisory Committee (MTAC) considers to have 'plausible promise' to deliver these benefits are selected for full evaluation. A guidance is produced after clinical and cost evidence submitted by the sponsor is independently assessed by an External Assessment Centre (EAC) and after a public consultation period. Devices and diagnostic tools with more complex value propositions can be routed for evaluation through other NICE programmes, such as the Diagnostics Assessment Programme or Technology Appraisals. NICE has previously described the methods used by MTEP in more detail [1] . This article presents a summary of the EAC report for Parafricta Bootees and Undergarments to reduce skin breakdown in people with, or at risk of, pressure ulcers (PUs). It is part of a series of NICE Medical Technologies Guidance summaries being published in Applied Health Economics and Health Policy.
Background to the Condition and Its Treatment
Pressure ulcers (also known as decubitus ulcers or pressure sores) are areas of localised skin damage caused by a number of intrinsic and extrinsic factors causing skin breakdown. Although anyone can develop a pressure ulcer, patients are at increased risk if they have significantly limited mobility (for example, people with a spinal cord injury); have a previous pressure ulcer; are at risk of nutritional deficiency; are unable to reposition themselves; or have a neurological condition or significant cognitive impairment. Pressure ulcers usually develop in people who have underlying health conditions or who have frail skin for whatever reason. Pressure ulcers tend to affect people with health conditions that make it difficult to move, especially those confined to lying in a bed or sitting for prolonged periods of time. They tend to occur more often in the elderly but can occur at any age. Conditions that affect the flow of blood through the body, such as type 2 diabetes, can also make a person more vulnerable to pressure ulcers. It is estimated that 412,000 people will develop a new pressure ulcer annually in the NHS [2] .
Pressure ulcers can develop when a large amount of pressure is applied to an area of skin over a short period of time or when less pressure is applied over a longer period of time, and they tend to develop over bony prominences, particularly the heels and the sacrum. The extra pressure disrupts the flow of blood through the skin. Without a blood supply, the affected skin becomes starved of oxygen and nutrients, and it begins to break down, leading to formation of an ulcer. Skin damage is also believed to be caused by friction, shear and moisture [3] , but the extent of the contribution of these is small-7.5 % in a sample of 28,299 hospital patients [4] and 13.9 % in a sample of 17,966 long-term care residents [5] .
Pressure ulcers are classified into four grades [6] :
• Grade 1: the affected area of skin appears discoloured; it is red in white people and purple or blue in people with darker-coloured skin. It does not turn white when pressure is placed on it, and the skin remains intact but may hurt or itch. It may also feel either warm and spongy, or hard.
• Grade 2: some of the epidermis or the dermis is damaged, leading to skin loss. The ulcer looks like an open wound or a blister.
• Grade 3: skin loss occurs throughout the entire thickness of the skin, and the underlying tissue is also damaged, but the muscle and bone are not damaged.
The ulcer appears as a deep, cavity-like wound.
• Grade 4: the skin is severely damaged, and the surrounding tissue becomes necrotic. The underlying muscles or bone may also be damaged. People with grade 4 pressure ulcers have a high risk of developing a life-threatening infection.
For some people, pressure ulcers are an inconvenience, which require minor nursing care. For others, they can be serious and lead to life-threatening complications, such as blood poisoning or gangrene. In people with diabetes mellitus, they are a cause of foot amputations. Pressure ulcers can lead to delayed hospital discharge, but it is currently unclear how much of this is happening in the NHS. It is estimated that the cost per patient to heal an ulcer varies from £1214 for grade 1 to £5241 for grade 2, £9041 for grade 3 and £14,108 for grade 4 [7] .
Treatment for pressure ulcers includes regularly changing a person's position; using dressings, creams and gels designed to speed up the healing process and relieve pressure; and using equipment to protect vulnerable parts of the body, such as specially designed mattresses and cushions. Regarding the latter, the draft NICE guidance states that ''Pressure redistributing devices are widely accepted methods of trying to prevent the development of pressure areas for people assessed as being at risk. These devices include different types of mattresses, overlays, cushions and seating. They work by reducing pressure, friction or shearing forces. There is limited evidence on the effectiveness of these devices'' [8] . For the most serious cases, surgery is sometimes recommended. One issue with all pressure relief equipment is the impact it has on the patient's ability to self-reposition and move around the bed. Much of the equipment currently in use in the NHS addresses the offloading issues in pressure ulcer prevention but does not address repositioning.
The Decision Problem

Population
The target population was any adults or children (excluding very young children) with, or at risk of, pressure ulcers in a hospital or community setting.
Intervention
The intervention was Parafricta, which can be in the form of one or two Bootees and/or an Undergarment. Parafricta is made from a proprietary fabric, which has a low friction coefficient, and the intended mode of action is to reduce the friction component of skin breakdown. The NICE final scope did not specify whether this referred to use of a single garment only or use of two or three garments together. Parafricta is used as an adjunct to pressure-reducing devices used in standard NHS clinical practice.
Comparators
The comparators in the NICE final scope were pressurereducing devices used in standard NHS clinical practice, and also one of the following three options: 1. No Parafricta (i.e. pressure-reducing devices alone). 2. Sheepskin. 3. Pressure-relieving bootees.
Outcomes
Relevant outcome measures included the following:
• Incidence of grade 1 or 2 pressure ulcers progressing to grade 3 or 4.
• Incidence of development of new pressure ulcers.
• Incidence of skin breakdown.
• Severity of pressure ulcers.
• Length of hospital stay.
• Time to healing for patients presenting with an existing pressure ulcer.
• Patient compliance with pressure ulcer management interventions.
• Patient comfort: including the ability to move and selfreposition in bed.
• Quality of life.
• Morbidity.
• Device-related adverse events.
Review of the Clinical and Economic Evidence
The sponsor submitted clinical and economic evidence based on the scope issued by NICE. The economic evidence included a de novo economic model. The EAC critically appraised the submission and carried out additional analyses to evaluate the outcomes identified in the scope.
Clinical Effectiveness Evidence
Sponsor's Review of Clinical Effectiveness Evidence
Seven studies were included in the submission, of which three were single case studies [9] [10] [11] ; two were small, uncontrolled case series [12, 13] ; one was a small, partially controlled case series [14] ; and one was a larger case series with documented historical controls [15] . There was also an unpublished audit (Gleeson [2014] . Heel pressure ulcers, where now? [unpublished manuscript]), which has now been published [16] . See Tables 1 and 2 for an overview of these studies. The submitted studies evaluated one Parafricta Bootee, one or two Bootees or Undergarments, or a combination of Bootees and Undergarments. The evidence is generalisable to the UK setting.
The three single case studies need no further description, and their results are presented in Table 2 . The case series by Loehne [12] gave no information on the study design other than that it was a case series of the use of Parafricta Bootees in nursing home patients. The study by Stephen-Haynes and Callaghan [13] was a case series of 25 nursing home residents, evaluating Parafricta Bootees and/or Undergarments added to a standard approach as outlined by the 2005 NICE guidance [3] . There was no comparator. The results of these studies are also presented in Table 2 .
The study by Hampton et al. [14] was a case series of 25 nursing home residents. A single Parafricta Bootee was used on the right heel in 10 patients, with the left heel used as a comparator. Eighteen patients had Parafricta Undergarments, and there was no comparison group. The duration of follow-up was 4 weeks. The outcomes were measured in three ways:
1. Bogginess and redness of the skin as assessed by the tissue viability nurse. 2. Colour photographs. 3. High-frequency ultrasound graphs.
The reason for the use of three different ways of measuring outcomes was the difficulty of assessing skin oedema. Bogginess and redness were judged to be very subjectively assessed. The colour photographs did not reproduce the nature of the skin damage well, as the colour reproduction depended on ambient light levels. The ultrasound graphs were an attempt to measure thickening of the skin from oedema; they were felt to be the most reliable For incidence of pressure ulcers and deterioration, see Table 3 No statistically significant The results suggested that heels with Parafricta Bootees became similar to normal heels within 4 weeks, and this was suggested to occur because of a reduction in skin oedema.
Smith and Ingram [15] recruited 165 patients in 3 months, who were compared with 204 historical controls recruited in the previous 3 months with a similar condition in the same hospital wards (two medical wards and one orthopaedic ward). All patients were at high risk of pressure ulcers (with a Waterlow score of C15); some had pressure ulcers on admission and some did not. All were unable to reposition independently. The intervention was the addition of a Parafricta Bootee and/or Undergarment to standard pressure ulcer preventative measures. The outcomes were the incidence, improvement and deterioration of pressure ulcers; and cost effectiveness. This study provided the effectiveness evidence for the economic model. Smith and Ingram analysed the results regarding pressure ulcer incidence, improvement and deterioration by using differences in the incidence. These are reproduced in Table 3 . As incidence differences are difficult to interpret, these were recalculated using relative risks (in Revman 5.2), and the results are shown in Table 4 . The results of the study (whichever way it is analysed) suggest that in the Parafricta cohort, there were fewer patients who developed pressure ulcers after having no pressure ulcers on admission, but there was no difference in the development of additional pressure ulcers in patients who already had a pressure ulcer. Also, the results suggest that fewer pressure ulcers deteriorated in the Parafricta cohort. There were no statistically significant differences in the length of stay between cohort 1 [no Parafricta] and cohort 2 [Parafricta], but the lengths of stay were not given. The results in terms of Waterlow scores are shown in Table 5 .
The audit at St Helen's and Knowsley NHS Trust (Gleeson [2014] . Heel pressure ulcers, where now? [unpublished manuscript]) [16] was of the use of Parafricta Bootees for patients considered at risk of a heel pressure ulcer, in comparison with the current practice of using a protective hydrogel dressing, which had not been published. This audit was started in 2013 and was planned to go on for 2 years, but the first year's results were available at the time of the appraisal. The unpublished 2014 manuscript by Gleeson described a clinical audit of the use of Parafricta Bootees in an unknown number of patients in six hospital wards at St Helens and Knowsley NHS Trust between January and December 2012, and was submitted as academic-in-confidence material. How the audit was conducted was unclear, as there were no details in the manuscript. The characteristics and results of the audit are presented in Table 2 . This study has since been published by Gleeson [16] , and the information in that publication remains consistent with that in the unpublished manuscript.
Critique of Clinical Effectiveness Evidence
Smith and Ingram [15] formed the basis of the economic model, so their study is discussed further here. It was a case series with historical controls, i.e. a single-centre, controlled, before-after study. According to the Cochrane Collaboration, in a study design such as that used by Smith and Ingram, in which there is only one intervention or control site, ''the intervention (or comparison) is completely confounded by study site making it difficult to attribute any observed differences to the intervention rather than to other site-specific variables'' [17] . Therefore, this study design provided relatively weak comparative evidence, as the observed results may have been due to confounding. As no numerical results regarding the length of stay by cohort, no numbers of deaths in either cohort and no demographic characteristics in either cohort or combined were given, it is impossible to tell how similar the cohorts were. The only information available was the Waterlow score from the economic submission, which suggested that the cohort not given Parafricta may have been more at risk of pressure ulcers than the cohort given Parafricta. The difference in pressure ulcers could also be due to the fact that the Parafricta cohort patients were less ill than those in the historical comparison cohort. Therefore, it cannot be inferred that any change in pressure ulcer incidence, improvement or deterioration was due to use of Parafricta Bootees and/or Undergarments. Additionally, as the patients in the study could not reposition themselves (an inclusion criterion for the study), they represented only a subset of the population who might potentially benefit from Parafricta. If patients could not reposition, then their movement would be limited, so it would be likely that any pressure ulcers that occurred would have been caused by pressure rather than friction.
Economic Evidence
Sponsor's Economic Submission
The study by Smith and Ingram [15] was the single economic study identified in the sponsor submission. This cost analysis estimated that use of Parafricta garments may reduce the cost of pressure ulcers by £637 per at-risk patient admitted to hospital, net of the costs of purchase and laundering. Costs were estimated from an NHS perspective, but the price base year was not explicitly stated. These savings were the result of the estimated reduced length of hospital stay experienced by patients using the Parafricta garments.
The sponsor acquired the raw data on the incidence of pressure ulcers and associated lengths of stay from that study and used the information as the basis of a new cost model. It used this information to conduct two separate analyses-one in a hospital setting and one in a community setting-to perform a cost analysis of use of Parafricta Bootees and Undergarments as an adjunct to other pressure-reducing devices used as standard in the NHS. Potential cost savings were driven by a reduction in the length of stay in the hospital model and by a reduction in nurse/carer interventions in the community model, reflecting a lower prevalence of pressure ulcers.
The hospital model consisted of five potential pathways for patients admitted to hospital and at risk of pressure ulcers: (1) admitted without pressure ulcer(s) and remained without; (2) admitted without pressure ulcer(s) but developed a pressure ulcer in hospital; (3) admitted with pressure ulcer(s) that did not deteriorate; (4) admitted with pressure ulcer(s) that deteriorated; and (5) admitted with pressure ulcer(s) and developed an additional pressure ulcer in hospital. The proportion of patients in each potential pathway for both the historical control group and the Parafricta group is shown in Fig. 1 , depicted as a decision tree. The median length of hospital stay for each of the pathways was weighted by the incidence. In the Microsoft Excel implementation of the model, relevant per-day costs were then applied to relevant proportions of the weighted stay on the basis of the expected time to development of an ulcer and the length of stay. Costs differed for those days spent without a pressure ulcer (where only general hospital costs were incurred) and days with a pressure ulcer. Dressing costs and per-day unit costs for the hospital stay [18] are detailed in Table 6 . This analysis estimated costs of £5307 per at-risk patient without use of Parafricta and £4550 per at-risk patient with use of Parafricta-a cost saving of £757. Some limited sensitivity analyses were performed, which suggested that the results were robust to assumptions.
The community model used data from the study by Smith and Ingram [15] and constituted a steady-state comparison of costs with and without use of Parafricta. Using the incidence of pressure ulcers among those patients without an ulcer on admission, and the length of stay after development of an ulcer as a proxy for duration, the point prevalence with and without use of Parafricta was estimated. It was assumed that without Parafricta, for every patient in the community with a pressure ulcer, there would be two other at-risk patients without a pressure ulcer. The sponsor stated that this was consistent with published audits of prevalence [3, 19] . Costs without Parafricta were then estimated on the basis of the cost of nurse visits/carer interventions (1.86 per week) related to prevalent pressure ulcer cases over a year of resource use. The costs, based on a relative prevalence ratio of 0.37, were £5899.92 without use of Parafricta and £2444.93 with use of Parafricta.
Supplementary Economic Analyses Conducted by the EAC
The EAC verified the sponsor's search strategies, and no additional economic studies were identified. The EAC validated the sponsor's economic model and reconstructed the decision tree for clarity as well as a validity check.
Minor errors in the unit costs used in the hospital model were encountered and rectified, uprating to 2013/2014 pounds sterling, where appropriate. A minor modelling anomaly, which led to double counting of some dressing costs, was also rectified. These changes did not have a substantial impact on the results, given the relatively small cost of dressings. The EAC noted that the costs associated with the pathways reflecting changes in the pressure ulcer condition for patients admitted with a pressure ulcer (pathways 3, 4 and 5) did not incur different costs. This differentiation had the effect of diluting the data on the length of stay, increasing uncertainty. Therefore, the EAC presented a slightly modified decision tree, encompassing pathways 3, 4 and 5 into one single pathway-'admitted with PU' (Fig. 2) .
The cost of a bed-day in the hospital model was revisited. The EAC acknowledged the difficulty in identifying an appropriate per-day cost of the 'hotel stay' alone but did not feel that the sponsor's estimate was [15] . PU pressure ulcer sufficiently robust. National reference costs [20] for excess bed days were used as a reasonable proxy. The study by Smith and Ingram [15] identified that the at-risk population was treated in general medical wards and in trauma and orthopaedic wards. The EAC therefore used excess bed days for general medicine wards and for trauma and orthopaedic wards, for the gamut of skin disorders (with and without intervention and the whole range of severity) to calculate weighted costs, which are shown in Table 7 . The sponsor's estimate of £325 may have been at the higher end of the bed-day cost. The EAC model used £234 as the base case and ran a sensitivity analysis of £328 as an upper limit. The sponsor's model had used median values for the length of stay in both the hospital and community models. Although the length-of-stay results may have been skewed, they reflected the nature of the length of stay as observed in NHS practice; some patients require a significantly longer time in hospital. It is hard to assume that these greater lengths of stay constitute outliers. For modelling purposes, an arithmetic mean would better represent the average length of stay experienced for each of these groups; thus, the EAC subsequently used mean values in the hospital and community cost models.
After rectification of minor errors, re-estimation of bedday costs and modification of the structure of the hospital model, supplementary analyses conducted by the EAC focused on attempting to account for the two main weaknesses identified in the economic modelling included in the submission:
• Adjusting the estimates of the patient length of hospital stay for potential confounders.
• Reflecting uncertainty in input parameters in a more comprehensive manner.
The sponsor provided the EAC with the raw data from the study by Smith and Ingram [15] . This information was reanalysed by the EAC to consider a limited number of confounders: the patient's sex, Waterlow score and ward of admission. A log-linear model of the length of stay was fitted on Parafricta use (1/0), sex (male/female), Waterlow score (medium/high risk) and ward of admission (medical 1/medical 2/orthopaedic). The model diagnostic tests confirmed a good fit. As expected, the model was able to Fig. 2 Modified decision tree constructed by the External Assessment Centre, showing the proportion of patients in each potential pathway for historical control subjects (with no use of Parafricta) and for patients with use of Parafricta in the study by Smith and Ingram [15] . PU pressure ulcer explain only about 4 % of the variation in the length of stay, as the potential predictors of the length of stay were limited. Nevertheless, it was thought to provide better estimates than unadjusted estimates. Lengths of stay and their standard errors for all potential pathways were then predicted from the model. The EAC version of the hospital model estimated the base-case cost saving to be £595, as opposed to the sponsor's estimate of £757. For the one-way sensitivity analysis with a bed-day costing £328, the cost saving increased to £863. The probabilistic sensitivity analysis suggested that in nearly 8 out of 10 occasions, use of Parafricta resulted in cost savings.
The use of adjusted mean length-of-stay data was fed into the community model to estimate a prevalence ratio. Probabilistic analysis incorporating distributions around the time to develop a pressure ulcer and the length of stay was not possible because a negative value of the duration of the ulcer could be encountered during distribution draws. An illustrative deterministic sensitivity analysis using upper and lower 95 % limits of the length of stay was performed to re-estimate cost savings. The EAC version estimated the cost saving in the community to be £2510 per annual prevalent case, as opposed to £3455 per annual prevalent case. The deterministic sensitivity analysis suggested that the cost saving could be between £2295 and £2799.
NICE Guidance
Preliminary Guidance
The evidence submitted by the sponsor and the EAC's critique of this evidence was presented to MTAC, which provided draft recommendations relating to Parafricta Bootees and Undergarments, following its meeting in May 2014. These were as follows:
1. Parafricta Bootees and Undergarments show potential to reduce the development and progression of skin damage caused by friction and shear in people with, or at risk of, pressure ulcers. However, more evidence for their effectiveness in clinical practice is needed to support the case for routine adoption of Parafricta Bootees and Undergarments in the NHS. 2. Research is recommended to address uncertainties about the claimed patient and system benefits of using Parafricta Bootees and Undergarments. This should take the form of comparative research against standard care, preferably carried out in secondary care for ease and speed of generating findings. The research should include development of criteria to recognise people who would most benefit from the technology in community and secondary care. NICE will explore the development of appropriate further evidence, in collaboration with the technology sponsor and with clinical and academic partners, and will review this guidance when substantive new evidence becomes available.
Consultation Response
During the consultation period, NICE received 19 consultation comments from four consultees (three NHS professionals and one manufacturer). The comments concerned further academic-in-confidence data and requests to focus the recommendations on the effect of Parafricta Bootees on skin breakdown of the heel in adults only. MTAC considered the further academic-in-confidence data and the suggested focus on the effect of the Bootees only. MTAC judged that significant uncertainties in the evidence base remained; thus, it could not recommend routine adoption of Parafricta in the NHS. There were, therefore, few changes made before publication of the final NICE guidance.
6 Key Challenges and Learning Points
Key Challenges
• The lack of good-quality comparative studies reduced the scope for a robust economic analysis.
• Ambiguity in the presentation of the sponsor's submission posed challenges for understanding of some of the basic ideas and facts used to describe the cost model and its inputs.
Learning Points
• Future studies should collect and record detailed data on potential confounding variables.
• Future submissions should, where possible, provide the raw data on which the economic model is based, as having raw data in this appraisal was very helpful for testing of the underlying assumptions and validity of the model.
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